Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IK Partners in the divestment of Carspect to TÜV SÜD
Mandate

Vinge advises IK Partners in the divestment of Carspect to TÜV SÜD

August 19, 2024 Banking and Finance M&A Financial Regulatory Real Estate and Construction Employment and Benefits Intellectual Property Commercial Agreements

Vinge has advised IK Partners and the other owners in connection with the divestment of Carspect Group Holding AB to TÜV SÜD Aktiengesellschaft. Carspect is a leading provider of vehicle inspections in Sweden, Estonia and Latvia, with a total of approximately 150 stations and over 500 employees.

Vinge's team consisted primarily of Jonas Bergström, Johanna Wiberg, Vilhelm Rondahl and Ida Appelgren (M&A), Lionardo Ojeda, Rebecka Margolin, Sofia Haggren and Nour Makie (Banking and Finance), ohan Cederblad (Permits & Accreditation), Kristoffer Larsson (Real Estate & Environment), Ebba Svenburg and Emil Lindwall (Employment Law), Martin Boström (Commercial Contracts / IT), Felizia Wiker (IP) and Anna Ekdahl Roos, Ellinore Boström Andersson and Gabriella Balbo (Transaction Support).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025